is This Mark. a solid for Thanks, quarter Ginkgo.
Google of well design and DNA in sets with lead deal to to us the AI application up Our proteins.
going signal Pfizer real commercial on that our progress in a of While a digging with is deal be I'm second. to
engineering cell We're relationship with young down So however, company. public building taking guidance. want address I as to a why we're you all our
so to while but want get to we as progresses also and want we year year-end. update And them ranges close we to the ambitious have achievable goals, tighten as
our venture reasons well biotech is for the we're as sector up, million provided that $XXX new million QX programs capital the drying engineering being that our counts down So to guidance industrial size last -- million.
Generally, we're revenue of impacts $XXX also than in million, and this QX, program as hoped reducing call $XXX to revising for the on which of our and lower services cell seeing from revenue. in components around $XXX to on the I
for flywheel lower want program better it's lot one I scale. our us metric counts Now up the And internally on being of a spend I here. we to some critical demonstrates that because attention at time that to Ginkgo, a pay get with spinning this is do
program and get. time, programs was But quarter, Ginkgo. So new want which infrastructure call an hoped explain it's been at particular, why we capabilities I sales in at than to Pfizer same is our our this out of new commercial to than stronger less here. the ever demonstration XX had our And important enterprise I it's with
they And same work they platform This secondly, area is other modality. the it, outsource several is deal And we've at doing emerging, like of in drug commercial especially tech. that discovery is as It's potential done words, of So This closing manufacturing Ginkgo.
And that think a they a discovery is a Jen is customers heads the not which doing to an of much R&D is mRNA new new deal like team. work discovery here us the biotech.
And do do that's which nor process that it's otherwise would I In as a of hundred than value is big easy then in Remember, millions in is platform not because should to and good more was our choose kind agricultural mRNA have our it's to convince I'm commercial is we work as Ginkgo's all okay? came that Ginkgo Wipf themselves, because up proving can to that first, this think customers. general closely right? downstream teams scalable, in a heavily to this who deals, scalable. have close, why for say that out previous we biopharma. it's to themselves. type our drug, is deal platform. deal a involved by because reason sell lead, not worth an normal wasn't to a myself at to mRNA dollars really right?
And this And sales from pointing deal important, is of right, tend number this drug is is the is high sales, Jen harder customers a that's out to as work biotech held deals therapeutics. mRNA I And all with this to with attached of so
during and is so enterprise fees company see are doing, the is industry and a like leadership on downstream negotiated types hundreds partnering technical like scalable, Ginkgo all deals a of millions and pharma biopharma large time typically team that the if royalties, up team CEO dollars of in biotech or Our milestones work, small were industry. of in they sales of the with deal press the by of plus type you popping involving Pfizer,
Ginkgo advantage being routine team by result led build a really able strategic to an deal who over engine in X Jen, here like for company sales team and commercial last to do great huge our a that work Ginkgo. is the heads the manner the enterprise of building, a years and at
And end QX, updated would which in coming that. something see this scaling that to further if be we that's XX high and sales up. guidance thrilled hit watching new XX the of we're programs, with I'll team to starts out I'm So of enterprise of would signal our the work be infrastructure, great a how program commercial
Finally, in new see Ginkgo, and over growth. the we're XX% happy Scale with cell engineering guidance, in at services revenue and looking XX% to to last XX% of that to the updated I'm growth programs still helps year. growth rate XX% so
Okay.
let's strategic in on X So topics. dive our
more recent So we're want so AI a first, I technology, case to share our doing little some customer studies, of what where we get there. apply sense you
I our of we asked, pipeline. to going most around excited I'm we're you what lot Second, future little sort it and understanding better defense a part about more programs.
And business want of security how going more biosecurity share get to and relates about how programs often about thinking is to most finally, actually, are then so the we're programs cell favorites. engineering. active of programs asked how share a national lot and pipeline, as program our not those as about pick to advanced, much where what those a technology there business, diversity But are all just I'm back infrastructure, that a get of in get importantly a data
Okay.
Let's in. jump
Okay.
and assets studies want show its I to first, into of application. talk some fits Ginkgo the AI other about of how So case
designs.
This about they scale, reminder, at we laboratories organized costs is in our that is a okay? generate and genetic different Boston talked foundry lower reused a at other automated Ginkgo. across Think In previously at can many data we for call is, what this programs. important customer base project from development testing into base, code our customer. data use words, a grow So foundry our our in lot factory A as like speed here the which code again, gets different better that from asset help project one scale. to another of second is And we data a
prices those exciting and of do train used to then upon okay? well way is those better should model models, milestone That's models just already be inform of also to And milestones. very exciting cost is models our something customers. biology our Google quarter, things. at at already did as measure with that our efforts certain making we Cloud. earn day. X by every to out a experiments sort also we've better use deal of expected Ginkgo.
We Ginkgo capacity to assets short of on to development It's gives Google large have cost our AI fund to represents compute scalable as achieved that feedback this a in function at going a by efforts been Ginkgo. attractive that announce our train relatively and a successful way models So data train to it's a Ginkgo And to but with we easier order.
One foundation to building enhance our second We're cash in making commitment development is loop, to making to engineer for can large what's completion That result good the very is here the models, our partnership it reminder, partnership first this this the these Google reducing and get
the various we miniaturization down automation, can increased on. that First, operation, cost reagents operations so through our so foundry, So less and we is right? use the liquid scale unit in per investments happening this of like and drive handling, in
the factory. engineering words, operations Second, much round tricky cycle. do requires other And need do of is that in how this do, design one of the judgment. because each how unit -- work number it per many In we we to need we
designs, that's thing tens money, a libraries, campaigns models we you can to we Ginkgo our learn. you it's something on the per the And to can the AI lot of that of campaign would early that can could increase mean right the less If a large get or quality how we more of do reduce right? those program, do, But Sometimes extent same of use try And more giant out you of do thousand uniquely infrastructure. which those because save the you and also can increase to designs. scale. those and run of want automation, fast really size scale that programs
very So exciting. it's
this this think do we a of Again, prior to certain why developed other into key is enough in us. budget.
All than in a ability up really the I much learning the working from biopharma, cycles, of and significantly what reducing need speed cycles the is especially about But from do much number that right. Finally, customers cycle. do model results, care for project. design number the programs are customers, that may we the that, so important, can depth. something often projects the to most is that because customer take spec be and we've other the of more in words, customer to In in about critical we've And done they exceed we it just learned like and a part speeds back feed words, with first areas, reinforcement
provider by an customer another with service this earlier those move, that to engineering right? wasn't us want in we So studies This So had that came their highlight share and sufficient need an is program case that's that A enzyme of produced how cool. case market. really to I meet study, the variables for year. we're the been started first enzyme them to a couple seeing
tested. you designs various the we can enzyme On see left, the
represents is the sequences It starting more Dots to sequence And the closer, that are in get, original. So similar way that that a are similar. are black us. sequences dot customer middle protein closer you starting further that to our sequence. the less the gave the the
so foundry is and where And this our of powerful. the combination really AI become
improvements see broadly enzyme is of of than step want. customers can and much an to to change afford get we is foundry tweaks over to typical. big First, the not over We because test again minor more that sufficient the kind
change So -- Many right? you of in the to change but protein lot, adding less sequences risky, all all tend adding that they is success. -- that a diversity, if have
can a much that more we And screen so so wider in of needle much can that stack. hay we enzymes space kind efficiently, search and find because
Second, predictive. our extremely are getting AI/ML models
both cycle, is use was the XXX here represented that cycle So as that those novel XXX-member well cycle. accuracy known customers' we base on models in we to highly discovered efficient by members tens better of speed. But big improved far left. first predicting sometimes with were as member we expectations Yes, enzyme ultimately, code the work, in the here, than an it thousands the customer.
And was really tested of our again, is from a enzymes. also relatively first original exceeding enzymes in able a And sequences do comprising in Each we library, a workflow of versus, would custom-engineered XXx the a win library dot what small our our just unlocked AI/ML the a design.
that's So exciting. really
big goal case will here is molecule over get out higher in titers, are had enzyme. production second X customer it to a putting that how which produce And out small to wanted do you X figure the a fermentation how a a The in than much this years, basically, the that rather customer around study like at to compound of These be tank. next this important they of second. to optimizing
than were for. to deliver what just outcome to And the faster than wanted couple customer we different so and they we strains, here, did and a cheaper a host they try it wanted. better us Originally, of able asked
in customer wanted that the first first So the on had it already by our were did what knowledge and of on This to the able the improve experiment, building us by in end and year, first titer done we we experiment, was get the code is we to XX.X-fold. our that base.
this knew well shelf. and could take off in just AI we which and them more genetic elements ones of this about the organism, and is less we the that we So worked had
end big that wouldn't powerful, That's didn't And code that Because we have of shelf. base, Okay. that again, titer strength originally the program, company able of we was is improvements, the take customer something towards. were years, off on deliver only us which of shelf to very working months the X almost by to could what took another XX the have we the which then instead X scale. XX-fold have double that
The something by of tools. driven and And similar last improvement enzyme that case is to Ginkgo range again, unique. second wide round machine was makes this of driven learning study. improvement the We draw a on
So in outcome together, this as outsized protein case, enabled shelf, the putting customer. as AI, that well genetic the elements off design by gave those for
tools So are integrating emphasize reducing our cannot we're started I'm improve with customer for said, I of of programs. in these equation, examples steps, cost like ability, of that efficiency time all to those different speeding a we're I excited this. into and super AI's customers. lines couple how getting about just AI hopefully
Okay.
Second topic.
programs. the customer rest pipeline at the of a look take of let's So
this. again, So here have at Ginkgo I about pipeline I a not my not drug own do have want does reminder, its Like Ginkgo. as very development be to clear pipeline. product own
gotten of percentage is I give this today I'm QX, to list.
In a programs customer our us saying programs. That and industrial pharma of a again, to demand. areas those and on get other move gets additional of don't them a work has words, pipeline you all progressing I'm I programs. work?
All about as platform had active again, to platform, color negotiate that in terms sign maturity. And So where to program of is, for important, -- see thinner, great think But had do on want when us a to an other technical their especially the making to this pipeline, of of it. the a undersell real number customer those piece words, programs biotech tighter. our are stand largest happy of to right? area through In outsource time, I really can this to we we highest right. get pharmaship. In have really strength It's they we up up how that's with is certain more If want that being that.
general biotech we've something is to got As moving, long as in do.
Okay.
this me. fun So chart is a to
As often pipeline drug a or XX biotech moving preclinical through maybe like a for would of show this that product-based traditional X assets trials. are and company sort clinical
a program. get great amount the asked And each the that on programs times of we'll many represents and bar X so in to is a program of slide. that the basis just This portion have that a XX% total we horizontal them tell show scale you portion are we like And on next program, over slide.
This rest programs page these the on fit complete. number Here, can't I making we of added the even point the of less an the you of was a excited on biotech is XX And here programs I'm industry. this. quarter, the give It's the were still really made a for cannot hoping. relative year-to-date right-hand dark earlier overview we why if than was just the side, chart, I progress the on as represents of the to of it in being see bar,
happy very of be it I'm sharing you. to all So with
this to there again, example. if people good out for to and clean We try do ask a it will is things, try get we up it
are So that the QX. program number at top, So at Ginkgo's were of that there programs that means are in XXX%, program as on concluded you okay? see a can that
you next to start gone, of right? we mix. again on some in be for this it see would shift slide, the the So And QX, can program do
a the programs half colors here, that more development see are you'll lot, So early efforts in of if you are -- newer look biopharma. recent our But given that again, of you the tricky. if colors our into biopharma, are just under in at
do, that.
All customer they some they So to see but if those then move to and fail I'm do, After they if they the with enter hit hit the XXX%, again, them, chooses XXX%, before commercialization. happy forward and right. programs -- customer
the regulatory meaning going programs like see is the is development. II scale with you taking can like product up, through bottom customers customer being this. them have are or Phase announce on we don't XX so in Synlogic now, into commercialized this trials that they're Again, like And moving forward actively Centrient.
Many
be us the that finishes. market. other So we've commercial. that where can on have. are program held a they or couple it close it's commercialization And put And X vest, have In customer equity into to programs words, the has giving they're shared that of kind but fully the process eventually, we royalties, a
hopefully these pipeline into the So you more we're coming see we're add quarters. XXX% get excited in to excited pipeline the very buckets of to to on as couple complete, the move the saw to many slides, and programs programs the extra last
So what platform many pretty rather all really, makes of slides. than a more all is a And in company Ginkgo really awesome in one biotech. It's we proud scale place. special scale. as this of it the I'm need product to this see
I'd about our in priority like and emerging around is the strategic this to position that's national Okay. space. Ginkgo's cover which for topic biosecurity the day, last security emerging
been this. U.S. to Capitol in spending London instead Hill of in advance good quite these at of both how I've of have bit few biotech, our AI Megan of leadership discussing Anna convergence to Anna new a to AI, presentation for past which in those to time start which bunch got AI a the linked space.
Last of General down Marie, during here, our Safety reading business, interested weeks, accelerate here, biology. the of responsibly. were the seen this why see Manager Summit is how technologies a Marie, AI of the discussion but the also biosecurity you around just are ton week, we've So And the and Matt McKnight, in in and discuss articles Head
for the reason irrespective And do So biosecurity needs while by throwing our this its humans. it whether of off potential we on own. to not, misuse exist, pandemics or for Nature and is, Mother epidemics is
with to And the it link to comes biodefense to recently, which ecosystem defense And read is particular ensure with building is regardless focus seeing way have seen be Shyam which I'd you of platform, clear Shyam's health. technology scalable needs business recently, security biology, COVID post talk believes leadership biosecurity a what I'll gap for and, government from done tools, Ginkgo mapping so like, deployed on that a defense out need really national Palantir, a more of more Board at say, public becoming but we years a advancement community big as our biodefense has that nice the is not what might clear blog a the to to Chair, our is There Sankar respond momentum critical we driving a tech been when a do biology. category. it biology can in global more tools yet protect now there. about increasingly is We're defense here. priority look for for in technologies more real responsibly.
We've AI to
Okay.
out third because therapeutics. at has box the part gets across So tech significant been And on and of the the and Ginkgo of plays to so in bottom, this and analytics "Wait most area control something investment but it vaccines stack then things we and gap monitoring been, a the response, of disease date that's infectious approach do our biodefense, see of in to as about has until for product investment it." kind like
a are with That's as to respond we early to it, after got can to we be overwhelming fact. able to work prevention hard but hey, And if damper on to the and opposed detection. -- and investment going put the been things happen,
calculus. impact I of has that COVID think the changed
effects a it, threat saying, up right? We AI looking want detect characterizing it different computer like addressing this Your cybersecurity, it the to able national and time In a comes monitoring to of constantly hey, it be mitigation And be want right to to about as we and let can to this that threat kind constantly we build the can't about. could it security to monitoring infrastructure something same thing. reduce just need of afterwards. the mitigation. exact bit than be is countries clean and even detection for and dangerous, you respond.
And vaccines. then to We the You have leverage think happen do mean biosecurity,
out, product type collection. This planes type voluntary and detect bioradar the wastewater monitoring. we're do building collect just you where is it airlines, from of product, passengers If exactly continuous anonymously swabs enough, of samples bioradar early enables snuff on this okay?
So you it from data from we infrastructure on our to
So we're but pathogen an targets. announced just with the We XX partnership our announced we just not over on this COVID, to expanding expansion of CDC just week.
little available genetic recent in these actually of pathogens data have publicly no years. Some to
up big means international XXX countries. in and visibility so originating already blind this with flights over more airports disease. We're we're So from far, expansion getting we're spots X running and that tackling into into some really
with addition -- as common In data. complex new animal by AI lot detection, epidemic X we're for Like with should be for to we're new and take working with is about consortium I a should and all going that partners Analytics and CDC spike? land weather, we would stuff? where should new already to infrastructure we're these our deepen sort integrating new routinely disease is samples bioinformatics, highlight in airports, now, progress that efforts spillover, engineering And Like excited going zones. our working hurricane better is to insights right And have build And kind progressing modeling. sort come find get of projects. And we I've a historical before, against what partnering And made methods to by to AI when tell right? zoonotic Center again, now from to will right? agricultural bioradar is to exactly tools prediction we've examining IARPA to our of really funded do this quarter, ways talked the it.
And better.
But and this you our This of USDA-funded for including be when genetic and disease. on monitor Forecasting data in, of work looking AI-based we're about measures to taken it of capabilities, continue analytical like platform use thing with the gets there, and the we're infectious for to it's
data analytic intelligence capabilities. conflict BIOINT risk global component and of like and these of as represent things BIOINT will and product all biointelligence our at the geopolitics, biological capabilities national of intersects with are accelerates critical novel for security foundation So a so
missile now but hurricanes, looking So is satellites, also for things okay, launches.
All this right. they're like for looking yes, they're
doing cause if to build out some a So see platform misuse, be want support we we BIOINT also monitoring want to type response and working something, someone can such to of detect and attribution, makers critical is We're that that address need How to of will here threats a is security scenario-based new decision and through threat? BIOINT What what we'll are do it, effectively do when lot than able outbreaks to emerge to what right. Where I can we biothreats easier does it's damage. before part that want can you when BIOINT about put last of It's they neutralize how? too lot if the And horizon? dangerous the be as on to questions countermeasures. work, a small it's it a fire late.
All this planning out for it?
And medical about that. key
understanding data bioradar Ginkgo's metagenomic is useful in cell does and for is better to our the to reused it's thing so this emerging platform. cell I an provide to make can sense feed analytics Finally, And side. our BIOINT, I a Cell business. to useful our think make want biology These can cell things for the pathogen. I engineering. alongside want With for we we training. business valuable for data Hey, have engineering more be biosecurity our also what product protein Biosecurity to This touch build together. on It's why tools on engineering platform Engineering understand
early new enable vaccines platform offerings So and develop another, Finally, that of both engineering build, our biosecurity we believe engineering use customers warning Our and help right? especially and biosecurity they'll could therapeutics cell one through and the grow, could develop our to also cell platform vaccines provide information countermeasures, help AI. right? continue our to therapeutics,
Okay. especially In and I great about with forward this demonstration our strategic the sales the looking Pfizer mentioned right. AI. engine with quarter, we've relationship And space.
All work growth I'm I'm the to summary, really continuing in this excited of program commercial done and Google our our
I'll for Megan Now hand to back it Q&A.
